Enright Patrick G's Form 4 filing
Zenas BioPharma, Inc. (ZBIO) · filed Sep 16, 2024
- Accession no.
- 0001104659-24-100333
- Filed
- Sep 16, 2024
- Trade date
- Sep 12-16, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market purchases total $7.48M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Enright Patrick GCIK 0001253886 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionAcquired | +723,812 | –F1 | – | 723,812 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +1,003,592 | –F4 | – | 1,727,404 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionAcquired | +334,530 | –F4 | – | 334,530 | Indirect | |
| Sep 16, 2024 | Common Stock | PPurchaseAcquired | +440,000 | $17.00 | +$7,480,000 | 774,530 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2024 | Common Stock | CConversionDisposed | −723,812 | –F1 | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −1,003,592 | –F1 | – | 0 | Indirect | |
| Sep 16, 2024 | Common Stock | CConversionDisposed | −334,530 | –F1 | – | 0 | Indirect | |
| Sep 12, 2024 | Common Stock | AGrant or awardAcquired | +37,000 | $0.00 | $0 | 37,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Referenced by the price of 1 transaction in Table I and 3 transactions in Table II.
- F4
On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
Referenced by the price of 2 transactions in Table I.